Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olanzapine intranasal - Impel Pharmaceuticals

Next Previous
Drug Profile

Olanzapine intranasal - Impel Pharmaceuticals

Alternative Names: INP 105; POD™ olanzapine

Latest Information Update: 13 Oct 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Impel NeuroPharma
  • Developer Impel Pharmaceuticals
  • Class Antidepressants; Antiemetics; Antimanics; Antipsychotics; Behavioural disorder therapies; Benzodiazepines; Mood stabilisers; Oxazepines; Piperazines; Small molecules; Thiazepines; Thiophenes
  • Mechanism of Action Dopamine D1 receptor antagonists; Dopamine D2 receptor antagonists; Serotonin 5-HT2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Aggression; Agitation

Most Recent Events

  • 26 Sep 2023 Impel Pharmaceuticals terminates phase-II CALM 201 trial in Agitation (In adolescents) in USA (Intranasal), due to business reason (NCT05163717)
  • 22 Feb 2023 Discontinued - Phase-I for Aggression (Intranasal)
  • 22 Feb 2023 Discontinued - Phase-I for Agitation (In volunteers) in Australia (Intranasal)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top